Patent intelligence · US
US 9849167
Compositions and methods for combination therapy with dengue virus and dendritic cells
Compositions and methods for combination therapy with dengue virus and dendritic cells
Patent details — US 9849167
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 26, 2017
- Expiration
- Dec 21, 2037
- Applicant
- PrimeVax Immuno-Oncology
- Claims
- 9
- CPC classes
- A61K, A61K2039/572, A61K2039/585, A61K2239/31
Quick answer
US 9849167 (Compositions and methods for combination therapy with dengue virus and dendritic cells) is held by PrimeVax Immuno-Oncology. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PrimeVax Immuno-Oncology
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/572, A61K2039/585, A61K2239/31, A61K2239/57, A61K35/76
More from PrimeVax Immuno-Oncology
Related pharmaceutical patents in our USPTO index.
-
US 12404275
Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
granted -
US 12383582
Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
granted -
US 12377115
Combination immunotherapies for treatment of cancer
granted -
US 12365719
CD80 extracellular domain polypeptides and their use in cancer treatment
granted -
US 12319738
Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
granted -
US 12304898
Quinolyl-containing compound and pharmaceutical composition, and use thereof
granted -
US 12234302
Chitosan derivatives and methods for preparing the same
granted -
US 12233119
Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
granted
Frequently asked questions
What is US patent 9849167?
US 9849167 (Compositions and methods for combination therapy with dengue virus and dendritic cells) is held by PrimeVax Immuno-Oncology. Status: granted. Granted Dec 26, 2017. Expires Dec 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9849167?
PrimeVax Immuno-Oncology is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 127 pharmaceutical patents for this assignee.
When does US 9849167 expire?
Our index shows an expiration date of Dec 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.